Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-212-3308500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions
What is Daxor's stock symbol?
Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."
Has Daxor been receiving favorable news coverage?
News articles about DXR stock have trended positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Daxor earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the near term.
Are investors shorting Daxor?
Daxor saw a decline in short interest during the month of February. As of February 28th, there was short interest totalling 236,283 shares, a decline of 8.7% from the February 15th total of 258,809 shares. Based on an average daily trading volume, of 29,158 shares, the days-to-cover ratio is presently 8.1 days. Approximately 30.1% of the shares of the stock are sold short. View Daxor's Current Options Chain.
Who are some of Daxor's key competitors?
Some companies that are related to Daxor include Tristel (TSTL), SDI (SDI), InfuSystem (INFU), TSO3 (TOS), Retractable Technologies (RVP), IsoRay (ISR), IsoRay (ISR), Omega Diagnostics Group (ODX), Milestone Scientific (MLSS), Relevium Technologies (RLV), Impression Healthcare (IHL), Vigil Health Solutions (VGL), Akers Biosciences (AKR), ANSELL LTD/S (ANSLY) and CONVATEC GRP PL/ADR (CNVVY).
What other stocks do shareholders of Daxor own?
Who are Daxor's key executives?
Daxor's management team includes the folowing people:
- Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
- Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
- Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)
- Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
- Mr. Guido Manzo, VP of Sales
How do I buy shares of Daxor?
Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Daxor's stock price today?
One share of DXR stock can currently be purchased for approximately $12.26.
How big of a company is Daxor?
Daxor has a market capitalization of $45.72 million.
What is Daxor's official website?
How can I contact Daxor?
Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500.
MarketBeat Community Rating for Daxor (NYSEAMERICAN DXR)
MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote "Outperform" if you believe DXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
